CareDx Announces Third Quarter 2026 Financial Results

CareDx, Inc. (CDNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CareDx Announces Third Quarter 2026 Financial Results Third Quarter Revenue Growth of 39% to $139 Million Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million BRISBANE, Calif. — (BUSINESS WIRE) — Car

Event · Earnings
Also in this documentGuidance · raise · $520M–$530M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 29, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CDNA
Bullish
high confidence
Mentioned
$CDNA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDNABullishHigh
01

Why it matters

The raised guidance reflects strong demand for testing services and successful recent acquisitions, likely boosting investor confidence.

02

Market read

First‑report earnings and guidance raise for a mid‑cap biotech, providing a clear catalyst for short‑term price movement.

03

What to watch

Potential integration risks from recent NavDx and Naveris acquisitions could temper upside.

Relevance 7/10Novelty 8/10Timing: after-hours
AlphAI · Earnings readCDNA · Third Quarter 2026 · ended September 30, 2026

Third Quarter Revenue Growth of 39% to $139 Million Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million

✓Strong quarter

Revenue increased 39% year-over-year to $139 million, Testing Services revenue increased 65%, GAAP net income was $19 million versus $2 million, adjusted EBITDA was $30 million versus $15 million, and the company raised both full-year revenue and Adjusted EBITDA guidance.

Revenue
$139M
39% y/y
Testing Services
$119M
65% y/y
Gross margin · GAAP
71 %
EPS · non-GAAP
$ 0.70
Full year 2026 outlook
$520 million to $530 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$139.4M–39%
Testing services revenueGAAP$119.2M–65%
Product revenueGAAP$ —––
Patient and digital solutions revenueGAAP$20.17M–31%
Testing Services volumeotherapproximately 75,900–51%
Testing Services revenue excluding revenue recognized for tests performed in prior periodsGAAP:null–approximately 58%
Testing Services revenue from tests performed in prior periodsGAAP$15M––
Specialty Oncology revenueGAAP$12M––
Cost of testing servicesGAAP$24.68M––
Cost of productGAAP$ —––
Cost of patient and digital solutionsGAAP$15.60M––
GAAP cost of salesGAAP40,287––
GAAP gross profitGAAP$99.08M––
GAAP gross marginGAAP71 %––
Non-GAAP gross profitnon-GAAP$102.5M––
Non-GAAP gross marginnon-GAAP74 %––
Research and developmentGAAP$21.32M––
Sales and marketingGAAP$31.65M––
General and administrativeGAAP$37.99M––
Total GAAP operating expensesGAAP$90.96M––
Total operating expensesGAAP131,250––
Non-GAAP research and development expensesnon-GAAP$20.13M––
Non-GAAP sales and marketing expensesnon-GAAP$30.00M––
Non-GAAP general and administrative expensesnon-GAAP$25.14M––
Total Non-GAAP operating expensesnon-GAAP$75.27M––
Income (loss) from operationsGAAP8,112––
Interest income, netGAAP2,208––
Other income (expense), netGAAP372––
Total other incomeGAAP2,580––
Income before income taxesGAAP10,692––
Income tax benefitGAAP8,600––
GAAP net incomeGAAP$19.29M––
GAAP net income marginGAAP14 %––
GAAP basic net income per shareGAAP$ 0.37––
GAAP diluted net income per shareGAAP$ 0.35––
Non-GAAP net incomenon-GAAP$38.37M––
Non-GAAP basic net income per sharenon-GAAP$ 0.74––
Non-GAAP diluted net income per sharenon-GAAP$ 0.70––
Adjusted EBITDAnon-GAAP$30.50M––
Adjusted EBITDA marginnon-GAAP22 %––
Net cash provided by operating activitiesGAAP$12.72M––
Capital expendituresGAAP−$1.61M––
Free cash flownon-GAAP$11.10M––

Segments

SegmentRevenueq/qy/y
Testing ServicesGrowth included $12 million in Specialty Oncology revenue and contributions following the acquisition of NavDx; Testing Services revenue also included $15 million in prior period revenue.$119M–65%
Patient and Digital SolutionsDriven primarily by continued growth in CareDx Pharmacy services.$20M–31%
Lab ProductsThe Company completed the divestiture of its Lab Products business on June 30, 2026, and third quarter 2026 results do not include Lab Products revenue.$ —––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Revenue$520 million to $530 million
  • NoteAdjusted EBITDA of $90 million to $100 million
  • NotePreviously disclosed revenue range of $490 million to $500 million
  • NotePreviously disclosed Adjusted EBITDA range of $66 million to $78 million

What drove it

  • Testing Services revenue increased 65% year-over-year, including $12 million in Specialty Oncology revenue.
  • Testing Services volume increased 51% year-over-year, including contributions from Specialty Oncology.
  • Patient and Digital Solutions revenue growth was driven primarily by continued growth in CareDx Pharmacy services.
  • Adjusted EBITDA was driven by revenue growth, higher gross profit and disciplined operating expense management.
  • The Company closed the acquisition of Naveris, Inc. on July 1, 2026 for $160 million in cash consideration and up to $100 million in contingent consideration.
  • The Company advanced AlloHeme toward a planned first-quarter 2027 commercial launch and HistoMap Kidney toward broader commercial availability in 2027.

Concerns

  • Testing Services revenue included $15 million in prior period revenue, compared with $6 million in the third quarter of 2025.
  • GAAP gross margin was 71 %, compared with 74 % in the three months ended June 30, 2026.
  • Net cash provided by operating activities was $ 12,718, compared with $ 37,358 in the third quarter of 2025.
  • The Company recorded $ 5,527 of business development and portfolio optimization expense, primarily related to the sale of its Lab Products business and acquisition of Naveris, Inc.
  • The Company completed the divestiture of its Lab Products business on June 30, 2026; third quarter 2026 results do not include Lab Products revenue.

What to watch

  • Execution toward the planned first-quarter 2027 commercial launch of AlloHeme and broader commercial availability of HistoMap Kidney in 2027.
  • Testing Services volume and the contribution from Specialty Oncology following the acquisition of NavDx.
  • The magnitude of revenue recognized for tests performed in prior periods.
  • CareDx Pharmacy services growth within Patient and Digital Solutions.
  • Migration of NavDx to the CareDx billing platform and continued Epic Aura adoption.
  • Delivery against full-year 2026 revenue guidance of $520 million to $530 million and Adjusted EBITDA guidance of $90 million to $100 million.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 250,480 as of September 30, 2026, compared with $ 65,429 as of December 31, 2025.
  • Marketable securities were $ — current and $ — non-current as of September 30, 2026, compared with $ 111,779 current and $ 24,165 non-current as of December 31, 2025.
  • Total assets were $ 641,457 as of September 30, 2026, compared with $ 413,228 as of December 31, 2025.
  • Total liabilities were 174,001 as of September 30, 2026, compared with 110,127 as of December 31, 2025.
  • Contingent consideration, non-current was 14,035 as of September 30, 2026, compared with 161 as of December 31, 2025.
  • Total stockholders’ equity was 467,456 as of September 30, 2026, compared with 303,101 as of December 31, 2025.
  • Net cash provided by operating activities was $ 12,718, capital expenditures were $ (1,615), and free cash flow was $ 11,103 for the three months ended September 30, 2026.

Analysis

CareDx reported third-quarter total revenue of $139 million, up 39% year-over-year from $100 million. Testing Services revenue was $119 million, up 65% year-over-year, while Patient and Digital Solutions revenue was $20 million, up 31%. Testing Services volume increased 51% year-over-year to approximately 75,900. The revenue mix included $12 million in Specialty Oncology revenue and $15 million in Testing Services revenue recognized for tests performed in prior periods.

Profitability improved substantially year-over-year. GAAP net income was $19 million, compared with $2 million, and GAAP diluted net income per share was $0.35, compared with $0.03. Adjusted EBITDA was $30 million, compared with $15 million, with adjusted EBITDA margin of approximately 22%, compared with approximately 15%. GAAP gross margin was 71%, compared with 69% in the third quarter of 2025, while non-GAAP gross margin was 74%, compared with 71%.

Sequentially, GAAP total revenue was $139,362, compared with $131,948 in the three months ended June 30, 2026. GAAP gross margin was 71%, compared with 74%, while adjusted EBITDA increased to $30,496 from $24,804 and adjusted EBITDA margin increased to 22% from 19%. GAAP net income for the June quarter was $110,636 and included a $112,966 gain on sale of the Lab Products business in the adjusted EBITDA reconciliation.

The balance sheet reflected $250,480 of cash and cash equivalents at September 30, 2026, versus $65,429 at December 31, 2025. The company closed the Naveris acquisition on July 1, 2026 for $160 million in cash consideration and up to $100 million in contingent consideration. Third-quarter net cash provided by operating activities was $12,718 and free cash flow was $11,103.

Management raised full-year 2026 revenue guidance to $520 million to $530 million from $490 million to $500 million and raised Adjusted EBITDA guidance to $90 million to $100 million from $66 million to $78 million. The operational focus includes the planned first-quarter 2027 commercial launch of AlloHeme, broader HistoMap Kidney commercial availability in 2027, scaling Specialty Oncology, and the migration of NavDx to the CareDx billing platform.

Management, verbatim

We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.

John Hanna, President and Chief Executive Officer of CareDx

We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.

John Hanna, President and Chief Executive Officer of CareDx

Not in the filing

stated, not guessed
  • A separate previous-release outlook section was not provided; therefore, no actual-versus-prior-guidance comparison is presented.
  • Debt balances were not reported in the provided balance sheet.
  • Share repurchases and dividends were not reported.
  • Full-year 2026 guidance for gross margin, operating expenses, tax rate, GAAP net income, GAAP EPS, operating cash flow and free cash flow was not reported.
  • Prior-year and prior-quarter Testing Services volume figures were not reported.
  • Year-over-year and sequential percentage changes for most statement-of-operations line items were not reported.
  • A numeric value for Testing Services revenue excluding revenue recognized for tests performed in prior periods was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

CareDx is a Nasdaq‑listed precision‑medicine diagnostics company focusing on transplant, oncology, and cell‑therapy testing.

Company-level read

Ticker impact

$CDNABullishHigh confidence
Context

CareDx reported Q3 2026 results with revenue up 39% YoY and raised full-year 2026 revenue guidance to $520‑$530M.

Expected impact

likely upward pressure as investors price in higher revenue and EBITDA outlook

Evidence & confidence

The company disclosed higher revenue and EBITDA guidance for the full year, a material update that can move the share price in the near term.

Market effects

Strengthens the transplant and specialty oncology diagnostics sector, signaling demand growth.

Positive for US biotech and healthcare investors, may lift peer valuations.

Limited to healthcare/diagnostics niche; no broad macro effect.

Counterpoint

If the guidance raise is already priced in, the stock could face a short‑term pull‑back.

Key entities

  • John Hanna

    President and CEO of CareDx, quoted on the results.

Every CDNA earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.